Key result
Intranasal and intramuscular administration of AAV vectors expressing SARS-CoV-2 spike proteins elicited robust and sustained neutralizing antibodies in mice for over a year.
Why the study?
The COVID-19 pandemic continues to pose significant health challenges despite existing vaccines, warranting evaluation of recombinant AAV expressing SARS-CoV-2 spike proteins.
Answers are grounded in this paper and cite their sources.
Sustained anti-spike responses via AAV vectors in mice; hypothesis-generating for durable vaccine platforms, human trials needed before clinical consideration.
The COVID-19 pandemic continues to pose significant health challenges, despite existing vaccines. This study evaluates the immunogenicity of recombinant adeno-associated viruses (AAV) expressing SARS-CoV-2 spike proteins, administered intramuscularly and intranasally in mice. Both delivery methods of AAV5-spike, AAV5-spike stabilized trimer as well as AAV44.9-spike elicited robust serum anti-spike antibodies within 8-12 weeks, with high levels of anti-spike antibodies sustained for over a year. Comparison of mouse serum antibodies 16 weeks post intramuscular or intranasal AAV5 administration demonstrated similar SARS-CoV-2 spike binding neutralizing activity in vitro. Analysis of changes in cellular immunity by ELISpot at 12 weeks post-AAV spike transduction revealed interferon-γ induction in response to peptide challenge. Despite a decline in AAV vector DNA at the injection site, the persistence of anti-spike antibodies demonstrated that AAV-vectors can elicit lasting immune responses, highlighting nasal AAV administration as a potential strategy to block respiratory virus infections.
No takes yet. Share an insight, caveat, or question.
Ji et al. (2025) studied SARS-CoV-2 vaccination. AAV expressing SARS-CoV-2 spike proteins vs. Untransduced control mice / AAV5-GFP was evaluated on Anti-spike IgG levels and neutralizing activity. Intranasal and intramuscular administration of AAV vectors expressing SARS-CoV-2 spike proteins elicited robust and sustained neutralizing antibodies in mice for over a year.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: